Year: 2017
Type: review
Abstract: PURPOSE OF REVIEW: Niemann-Pick disease type C (NP-C) is a neurovisceral disorder that may be more prevalent than earlier estimates. Diagnosis of NP-C is often delayed; a key aim for clinical practice is to reduce this delay. Recently, substantial progress has been made in the field of NP-C screening and diagnosis, justifying an update to the existing recommendations for clinical practice. RECENT FINDINGS: New biomarker profiling and genetic analysis technologies are included as first-line diagnostic tests for NP-C. Most diagnoses can now be confirmed by combination of biomarker and genetic analyses. Filipin staining may facilitate diagnosis in uncertain cases. Recommendations are provided for psychiatrists, neuro-ophthalmologists, and radiologists, and on screening within specific at-risk patient cohorts. The NP-C diagnostic algorithm has been updated and simplified. SUMMARY: This publication provides expert recommendations for clinicians who may see patients presenting with the signs and symptoms of NP-C, including general practitioners, pediatricians, neurologists, and psychiatrists.
Source: Neurology Clinical Practice
Authors: Marc C. Patterson, Peter Clayton, Paul Gissen, Mathieu Anheim, Peter Bauer, Olivier Bonnot, Andrea Dardis, Carlo Dionisi-Vici, Hans-Hermann Klünemann, Philippe Latour, Charles M. Lourenço, Daniel S. Ory, Alasdair Parker, Miguel Pocoví, Michael Strupp, Marie T. Vanier, Mark Walterfang, Thorsten Marquardt
Institutions: Mayo Clinic, University College London, Great Ormond Street Hospital, Centre National de la Recherche Scientifique, Inserm, Institut de génétique et de biologie moléculaire et cellulaire, Hôpitaux Universitaires de Strasbourg, Hôpital d'Hautepierre, Université de Strasbourg, Centre Hospitalier Universitaire de Nantes, Nantes Université, Hospices Civils de Lyon, Washington University in St. Louis, Universidad de Zaragoza, The University of Melbourne
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: Michael J. Fox Foundation for Parkinson's Research, Amgen, Eli Lilly and Company, AstraZeneca, GlaxoSmithKline, Sanofi, Biogen, Teva Pharmaceutical Industries, Alexion Pharmaceuticals, Wellcome Trust, Les Laboratories Pierre Fabre, GW Pharmaceuticals, LAM Therapeutics, National Institute for Health and Care Research, European Commission, Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Fondazione Telethon, Eisai, Fondazione Pierfranco e Luisa Mariani, Swedish Orphan Biovitrum, Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares, H. Lundbeck A/S, National Institutes of Health, Sanofi Genzyme, National Heart, Lung, and Blood Institute, National Institute of Neurological Disorders and Stroke, Actelion Pharmaceuticals
OpenAlex ID: W2765432893
